WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com. An audio replay of the call will be available beginni ...

Core Points - Stryker will report its financial results for the second quarter of fiscal year 2025 on July 31, 2025 [1] - A press release with summary financial information will be available at approximately 4:05 p.m. ET on the same day [1] - The company will host a webcast at 4:30 p.m. ET to discuss the second quarter results, with an archive available two hours after the live call [2] Company Overview - Stryker is a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3] - The company impacts over 150 million patients annually through its offerings [3]

Financial Data and Key Metrics Changes - The company reported a revenue of $800,000 for the last quarter, with a test volume of 3,034, which is at the upper end of the target range of 2,500 to 3,000 tests per quarter [9] - A significant balance sheet improvement was noted with a public offering netting $16,100,000, resulting in a pro forma cash position of $40,000,000 at the end of Q1, extending the runway well into 2026 [10] - The company achieved a large GAAP net income of $18,600,000 before non-controlling interest and preferred dividends, resulting in a positive primary EPS of $1.28 and a positive diluted EPS of $0.34 [22][23] Business Line Data and Key Metrics Changes - Lucid, the diagnostic subsidiary, is positioned to capitalize on a large clinical and market opportunity, with ongoing efforts to secure Medicare coverage [6][11] - Verus has restarted the development of a key implantable physiologic monitor, with favorable engagement from the FDA and a targeted filing for the first half of 2026 [12] - The incubator PMX is focusing on the PortIO implantable intraosseous device, with discussions ongoing with potential strategic partners [13] Market Data and Key Metrics Changes - The company is seeing momentum in new sales channels, particularly in concierge medicine and employer market contracts, which are expected to impact revenue in the second half of the year [10][11] - The company has a significant equity method investment balance of almost $47,000,000 reflecting a gain of $21,000,000 since year-end, representing an 82% increase in Lucid's stock price [18][19] Company Strategy and Development Direction - The company aims to diversify into the biopharma space, leveraging its infrastructure and management services model to pursue attractive biopharma assets [8][36] - The strategic vision includes expanding partnerships and exploring new opportunities while maintaining focus on existing subsidiaries like Lucid and Verus [53][54] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning and ability to execute on strategic initiatives, highlighting the strong relationships with key cancer centers and the positive feedback from pilot programs [30][31] - The management team believes that the current market conditions will not hinder their ability to raise capital, citing successful recent financings [46][48] Other Important Information - The company has deconsolidated Lucid from its financial statements, which has impacted the historical understanding of its financials [16][21] - The company continues to explore additional assets and opportunities to diversify its portfolio, with a focus on maintaining operational independence among its subsidiaries [8][40] Q&A Session Summary Question: Feedback from the pilot program - Management received excellent feedback from the pilot program, meeting all pre-specified performance metrics and demonstrating clinical success [29][30] Question: Exclusive rights to the platform - There are no exclusive rights limiting broader commercialization; the agreement allows for a registry and initial implantable procedures at the cancer center [32][33] Question: Strategic rationale for biopharma expansion - The company is leveraging its infrastructure and management services to pursue biopharma opportunities, which align with its history of adapting to market needs [36][39] Question: Impact of market volatility on capital raising - Management indicated that market volatility has not affected their ability to raise capital, with successful recent financings demonstrating investor confidence [46][48]

Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acq ...

Financial Performance - Company reported net revenues of $700.7 million for the first quarter of 2025, a decrease of 5.0% compared to $737.8 million in the prior year period [8][34] - GAAP diluted earnings per share (EPS) from continuing operations was $2.07, compared to $0.33 in the prior year period [8][46] - Adjusted diluted EPS from continuing operations was $2.91, down from $3.21 in the prior year period [8][46] Revenue by Segment - In the Americas, net revenue was $475.7 million, down 3.7% from $494.0 million [5][34] - EMEA segment reported net revenue of $151.2 million, a decrease of 5.3% from $159.6 million [5][34] - Asia segment saw a decline of 12.4%, with revenues of $73.8 million compared to $84.2 million [5][34] Revenue by Product Category - Vascular Access category reported revenues of $182.4 million, a slight increase of 0.6% from $181.4 million [7][34] - Interventional category revenues increased by 2.1% to $137.5 million from $134.7 million [7][34] - Anesthesia revenues decreased by 10.1% to $86.6 million from $96.4 million [9][34] Guidance and Outlook - Company raised its full-year 2025 revenue growth outlook on a GAAP basis to a range of 1.28% to 2.28% [10][11] - Adjusted diluted EPS guidance for 2025 was lowered to a range of $13.20 to $13.60, down from $13.95 to $14.35 [11][12] - Expected impact from tariffs in 2025 is approximately $55 million, which will be recorded in cost of goods sold [8][11] Strategic Initiatives - Company is evaluating strategies to mitigate exposure to tariffs and remains focused on executing its plan for the year [3] - Plans to separate Teleflex into two independent publicly traded companies, with significant third-party interest in acquiring NewCo [3]

Company Overview - Teleflex Incorporated is a global provider of medical technologies focused on improving health and quality of life [2] - The company aims to become the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [2] Product Portfolio - Teleflex is home to several trusted brands such as Arrow™, Barrigel™, Deknatel™, QuikClot™, LMA™, Pilling™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [3] Upcoming Events - Management of Teleflex will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 1:40 p.m. (PT) [1] - A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website [1]

Contacts For investor inquiries: Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com Portage, Michigan, April 29, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2025 Global Healthcare Conference on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Preston Wells, Vice President and Chief Financial Officer, and Jason Beach, Vice President, Finance and Inves ...

Investment Rating - The report provides a short-term investment focus on specific companies across various sectors, highlighting preferred and risk names based on tariff impacts [7][30]. Core Insights - The report analyzes the implications of the Trump administration's tariffs on nine major sectors, emphasizing the direct and indirect impacts on individual companies and their stock performance [6][30]. - The automotive sector is expected to face significant price increases due to tariffs, with an estimated 11.5% rise in US auto prices, translating to approximately $5,100 per vehicle [9][17]. - The report identifies key companies within each sector that are likely to be affected by tariffs, providing a detailed analysis of their potential performance [4][30]. Sector Summaries Autos and Auto Parts - Tariffs on automobiles could lead to a gross impact on operating profit ranging from 30% to over 100% for various automakers, with Toyota and Honda facing a manageable impact while Nissan and Mazda are at higher risk [4][9]. - Focus is placed on Toyota Motor for its resilience and ability to raise prices, while Bridgestone is noted for its high local production ratio [30][31]. Banks - The impact of tariffs on banks remains uncertain, but concerns over worst-case scenarios have eased, with a potential downside risk of slightly over 10% to sector earnings forecasts in a bearish scenario [4][33]. - Japan Post Bank is highlighted as a relatively stable option amidst tariff uncertainties [4][33]. Pharmaceuticals and Medical Devices - Major pharmaceutical companies like Takeda and Astellas are expected to be heavily impacted by tariffs, while companies with lower US sales ratios may benefit from tariff avoidance [4][30]. - The report emphasizes the potential for increased costs of goods sold (CoGS) affecting operating profits for medical device companies [4]. Technology - The technology sector's tariff impact is complex, with companies like NEC and Fujitsu expected to perform well due to limited exposure to tariffs [5][30]. - Sony Group is under close observation for potential price hikes on its products, particularly the PlayStation 5 [5][30]. Chemicals and Steel - In the chemicals sector, companies like Nippon Paint are expected to benefit from lower raw material prices, while the steel sector is anticipated to experience limited direct tariff impacts [5][30]. - Kobe Steel is noted for its resilience due to a significant earnings contribution from its machinery business [5][30]. Retail - The retail sector is advised to focus on drugstores and discount retailers, with companies like Asics and Fast Retailing facing risks from declining sales due to high tariff exposure [5][30]. - Seven & i Holdings is highlighted as particularly vulnerable due to its significant exposure to the US market [5][30].